SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on October 24, 2002; DOI 10.1182/blood-2002-06-1831. This Article Full Text Full Text (PDF) All Versions of this Article: 2002-06-1831v1 101/5/1698    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ogawa, H. Articles by Sugiyama, H. Search for Related Content PubMed PubMed Citation Articles by Ogawa, H. Articles by Sugiyama, H. Related Collections Oncogenes and Tumor Suppressors Gene Expression Clinical Trials and Observations Neoplasia Related Letter in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 March 2003, Vol. 101, No. 5, pp. 1698-1704 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia Hiroyasu Ogawa, Hiroya Tamaki, Kazuhiro Ikegame, Toshihiro Soma, Manabu Kawakami, Akihiro Tsuboi, Eui Ho Kim, Naoki Hosen, Masaki Murakami, Tatsuya Fujioka, Tomoki Masuda, Yuki Taniguchi, Sumiyuki Nishida, Yusuke Oji, Yoshihiro Oka, and Haruo Sugiyama From the Department of Molecular Medicine, Osaka University Graduate School of Medicine, Japan; Department of Clinical Laboratory Science, Osaka University Medical School, Japan; and Department of Medicine, Osaka Minami National Hospital, Osaka, Japan. In acute-type leukemia, no method for the prediction of relapse following allogeneic stem cell transplantation based on minimal residual disease (MRD) levels is established yet. In the present study, MRD in 72 cases of allogeneic transplantation for acute myeloid leukemia, acute lymphoid leukemia, and chronic myeloid leukemia (accelerated phase or blast crisis) was monitored frequently by quantitating the transcript of WT1 gene, a "panleukemic MRD marker," using reverse transcriptase-polymerase chain reaction. Based on the negativity of expression of chimeric genes, the background level of WT1 transcripts in bone marrow following allogeneic transplantation was significantly decreased compared with the level in healthy volunteers. The probability of relapse occurring within 40 days significantly increased step-by-step according to the increase in WT1 expression level (100% for 1.0 × 102-5.0 × 102, 44.4% for 4.0 × 103-1.0 × 102, 10.2% for 4.0 × 104-4.0 × 103, and 0.8% for < 4.0 × 104) when WT1 level in K562 was defined as 1.0). WT1 levels in patients having relapse increased exponentially with a constant doubling time. The doubling time of the WT1 level in patients for whom the discontinuation of immunosuppressive agents or donor leukocyte infusion was effective was significantly longer than that for patients in whom it was not (P < .05). No patients with a short doubling time of WT1 transcripts (< 13 days) responded to these immunomodulation therapies. These findings strongly suggest that the WT1 assay is very useful for the prediction and management of relapse following allogeneic stem cell transplantation regardless of the presence of chimeric gene markers. © 2003 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letter in Blood Online: Usefulness of quantitative assessment of the WT1 gene transcript as a marker for minimal residual disease detection Daniela Cilloni, Enrico Gottardi, Milena Fava, Francesca Messa, Sonia Carturan, Alessandro Busca, Angelo Guerrasio, Giuseppe Saglio, Hiroyasu Ogawa, and Hiroya Tamaki Blood 2003 102: 773-774. [Full Text] [PDF] This article has been cited by other articles: K. Rezvani, A. S. M. Yong, S. Mielke, B. N. Savani, L. Musse, J. Superata, B. Jafarpour, C. Boss, and A. J. Barrett Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies Blood, January 1, 2008; 111(1): 236 - 242. [Abstract] [Full Text] [PDF] K. Rezvani, A. S. M. Yong, B. N. Savani, S. Mielke, K. Keyvanfar, E. Gostick, D. A. Price, D. C. Douek, and A. J. Barrett Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia Blood, September 15, 2007; 110(6): 1924 - 1932. [Abstract] [Full Text] [PDF] A. Dominietto, S. Pozzi, M. Miglino, F. Albarracin, G. Piaggio, F. Bertolotti, R. Grasso, S. Zupo, A. M. Raiola, M. Gobbi, et al. Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia Blood, June 1, 2007; 109(11): 5063 - 5064. [Full Text] [PDF] X.-S. Wang, Z. Zhang, H.-C. Wang, J.-L. Cai, Q.-W. Xu, M.-Q. Li, Y.-C. Chen, X.-P. Qian, T.-J. Lu, L.-Z. Yu, et al. Rapid Identification of UCA1 as a Very Sensitive and Specific Unique Marker for Human Bladder Carcinoma. Clin. Cancer Res., August 15, 2006; 12(16): 4851 - 4858. [Abstract] [Full Text] [PDF] M. Kletzel Why target the WT1 gene? Blood, June 15, 2006; 107(12): 4578 - 4579. [Full Text] [PDF] D. Steinbach, A. Schramm, A. Eggert, M. Onda, K. Dawczynski, A. Rump, I. Pastan, S. Wittig, N. Pfaffendorf, A. Voigt, et al. Identification of a Set of Seven Genes for the Monitoring of Minimal Residual Disease in Pediatric Acute Myeloid Leukemia Clin. Cancer Res., April 15, 2006; 12(8): 2434 - 2441. [Abstract] [Full Text] [PDF] H. Lapillonne, A. Renneville, A. Auvrignon, C. Flamant, A. Blaise, C. Perot, J.-L. Lai, P. Ballerini, F. Mazingue, S. Fasola, et al. High WT1 Expression After Induction Therapy Predicts High Risk of Relapse and Death in Pediatric Acute Myeloid Leukemia J. Clin. Oncol., April 1, 2006; 24(10): 1507 - 1515. [Abstract] [Full Text] [PDF] T. Azuma, T. Otsuki, K. Kuzushima, C. J. Froelich, S. Fujita, and M. Yasukawa Myeloma Cells Are Highly Sensitive to the Granule Exocytosis Pathway Mediated by WT1-Specific Cytotoxic T Lymphocytes Clin. Cancer Res., November 1, 2004; 10(21): 7402 - 7412. [Abstract] [Full Text] [PDF] Y. Oka, A. Tsuboi, T. Taguchi, T. Osaki, T. Kyo, H. Nakajima, O. A. Elisseeva, Y. Oji, M. Kawakami, K. Ikegame, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression PNAS, September 21, 2004; 101(38): 13885 - 13890. [Abstract] [Full Text] [PDF] P. Savage, L. Gao, K. Vento, P. Cowburn, S. Man, N. Steven, G. Ogg, A. McMichael, A. Epenetos, E. Goulmy, et al. Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen Blood, June 15, 2004; 103(12): 4613 - 4615. [Abstract] [Full Text] [PDF] D. Cilloni, E. Gottardi, M. Fava, F. Messa, S. Carturan, A. Busca, A. Guerrasio, G. Saglio, H. Ogawa, and H. Tamaki Usefulness of quantitative assessment of the WT1 gene transcript as a marker for minimal residual disease detection Blood, July 15, 2003; 102(2): 773 - 774. [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020